Abstract
Non-albicans Candida species have acquired relevance in the last decades as a cause of serious disease. The virulence factors and antifungal susceptibility of these rare pathogens remain largely unrecognized. We examined a total of 50 yeast isolates corresponding to 11 different infrequently isolated yeast species for their in vitro enzymatic profile and susceptibility pattern as first-line antifungals. We found aspartyl protease activity for 100% of the isolates tested as well as variable DNAse, hemolysin, phospholipase and esterase activities. All strains had low MICs for amphotericin B and showed a variable response to fluconazole (0.125–32 µg/mL) and the echinocandins tested (0.25–> 8 µg/mL).
This is a preview of subscription content, log in via an institution to check access.
References
Capoor MR, Gupta DK, Verma PK, Sachdeva HC (2015) Rare yeasts causing fungemia in immunocompromised and haematology patients: case series from Delhi. Indian J Med Microbiol 33(4):576–579. https://doi.org/10.4103/0255-0857.167320
Chitasombat MN, Kofteridis DP, Jiang Y, Tarrand J, Lewis RE, Kontoyiannis DP (2012) Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. J Infectol 64(1):68–75. https://doi.org/10.1016/j.jinf.2011.11.002
Clinical and Laboratory Standards Institute (2017a) Reference method for broth dilution antifungal susceptibility testing of yeasts M27, 4th edn. Clinical and Laboratory Standards Institute, Wayne
Clinical and Laboratory Standards Institute (2017b) Performance standards for antifungal susceptibility testing of yeasts M60, 1st edn. Clinical and Laboratory Standards Institute, Wayne
de Salud Secretaría (2010) Diagnóstico y tratamiento de candidosis vulvovaginal en mujeres mayores a 12 años de edad. Diagnosis and treatment of vulvovaginal candidiasis in women over 12 years old. Health Ministry, Mexico City
de Salud Secretaría (2016) Diagnóstico y tratamiento de candidiasis orofaríngea en adultos en el primer nivel de atención. Diagnosis and treatment of oropharyngeal candidiasis in adults at the first level of care. Health Ministry, Mexico City
Fernández-Ruiz M, Guinea J, Puig-Asensio M, Zaragoza Ó, Almirante B, Cuenca-Estrella M, Aguado JM, CANDIDOP Project, GEIH-GEMICOMED (SEIMC), & REIPI (2017) Fungemia due to rare opportunistic yeasts: data from a population-based surveillance in Spain. Med Mycol 55(2):125–136. https://doi.org/10.1093/mmy/myw055
Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olvaei AJ, Marr KA, Pfaller MA, Chang C-H, Webster KM (2009) Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis 48(12):1695–1703. https://doi.org/10.1086/599039
Montoya AM, Sánchez González A, Palma-Nicolás JP, Gómez-Treviño A, González JG, González GM (2015) Genotyping, extracellular compounds, and antifungal susceptibility testing of Trichosporon asahii isolated from Mexican patients. Med Mycol 53(5):505–511. https://doi.org/10.1093/mmy/myv009
Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD (2016) Clinical practical guideline for management of candidiasis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis 62(4):e1–e50. https://doi.org/10.1093/cid/civ933
Perlin DS (2015) Echinocandin resistance in Candida. Clin Infect Dis 61(6):612–617. https://doi.org/10.1093/cid/civ791
Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Bijie H, Dzierzanowska D, Klimko NN, Letscher-Bru V, Lisalova M, Muehlethaler K, Rennison C, Zaidi M (2009) Results from the ARTEMIS DISK global antifungal surveillance study, 1997–2007 10.5-year analysis of susceptibility of noncandidal yeast species to fluconazole and voriconazole determined by CLSI standardized disk diffusion testing. J Clin Microbiol 47(1):117–123. https://doi.org/10.1128/JCM.01747-08
Richini-Pereira VB, Pires de Camargo RM, Bagagli E, Marques SA (2012) White piedra: molecular identification of Trichosporon inkin in members of the same family. Rev Soc Bras Med Trop 45(3):402–404. https://doi.org/10.1590/S0037-86822012000300025
Sanguinetti M, Posteraro B, Lass-Flörl C (2015) Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses 58(2):2–13. https://doi.org/10.1111/myc.12330
Taj-Aldeen SJ, AbdulWahab A, Kolecka A, Deshmukh A, Meis JF, Boekhout T (2014) Uncommon opportunistic yeast bloodstream infections from Qatar. Med Mycol 52(5):552–556. https://doi.org/10.1093/mmycol/myu016
Tosun I, Akyuz Z, Guler NC, Gulmez D, Bayramoglu G, Kaklikkaya N, Arikan-Akdagli S, Aydin F (2013) Distribution, virulence attributes and antifungal susceptibility patterns of Candida parapsilosis complex strains isolated from clinical samples. Med Mycol 51(5):483–492. https://doi.org/10.3109/13693786.2012.745953
Acknowledgements
This study was supported by Programa de Apoyo a la Investigación Científica y Tecnológica (PAICyT) (no. SA-1115-15). We thank Sergio Lozano-Rodriguez, M. D., of the “Dr. José E. González” University Hospital (Monterrey, Mexico) for his review of the manuscript prior to submission.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflicts of interest. All the experiments undertaken in this study comply with the current laws of the country where they were performed.
Additional information
Communicated by Erko Stackebrandt.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Montoya, A.M., Luna-Rodríguez, C.E., Gracia-Robles, G. et al. In vitro lytic activity and antifungal susceptibility of infrequently isolated yeasts. Arch Microbiol 201, 1147–1149 (2019). https://doi.org/10.1007/s00203-019-01684-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00203-019-01684-2